Identification of LY2510924, a novel cyclic peptide CXCR4 antagonist that exhibits antitumor activities in solid tumor and breast cancer metastatic models

Molecular Cancer Therapeutics

Volumn 14, Issue 2, 2015, Pages 480-490

  Peng, Sheng Bin ^a   Zhang, Xiaoyi ^a   Paul, Donald ^a   Kays, Lisa M ^a   Gough, Wendy ^a   Stewart, Julie ^a   Uhlik, Mark T ^a   Chen, Qi ^a   Hui, Yu Hua ^a   Zamek Gliszczynski, Maciej J ^a   Wijsman, John A ^a   Credille, Kelly M ^a   Yan, Liang Zeng ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; GUANOSINE TRIPHOSPHATE; LY 2510924; PROTEIN KINASE B; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG; CHEMOKINE RECEPTOR CXCR4; CYCLOPEPTIDE; LY2510924;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST METASTASIS; CELL MIGRATION; CELL PROLIFERATION; COLON CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG STABILITY; EXPERIMENTAL DOG; FEMALE; HUMAN; HUMAN CELL; IC50; IN VIVO STUDY; INTRACELLULAR SIGNALING; KIDNEY CARCINOMA; LUNG CANCER; LYMPHOMA; MALE; METASTASIS; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; TUMOR CELL; TUMOR GROWTH; U937 CELL LINE; XENOGRAFT; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CHEMISTRY; DISEASE MODEL; DOG; DRUG EFFECTS; DRUG SCREENING; EXPERIMENTAL MAMMARY NEOPLASM; MACACA FASCICULARIS; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMOKINE CXCL12; DISEASE MODELS, ANIMAL; DOGS; DRUG STABILITY; FEMALE; HUMANS; MACACA FASCICULARIS; MALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE, INBRED C57BL; NEOPLASM METASTASIS; PEPTIDES, CYCLIC; RATS, SPRAGUE-DAWLEY; RECEPTORS, CXCR4; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84923369983     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-0850     Document Type: Article

References (39)

1. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer 2004;4:540-50.
2. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001;410:50-6.
3. Orimo A, Gupta PB, Sgroi D, Arenzana-Seisdedos F, Delaunay T, Naeem R, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005;121:335-48.
4. Domanska UM, Kruizinga RC, Nagengast WB, Timmer-Bosscha H, Huls G, de Vries EGE, et al. A review on CXCR4/CXCL12 axis in oncology: no place to hide. Eur J Cancer 2013;49:219-30.
5. Staller P, Sulitkova J, Lisztwan J, Moch H, Oakeley EJ, Krek W. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumor suppressor pVHL. Nature 2003;425:307-11.
6. Peng SB, Peek V, Zhai Y, Paul D, Lou Q, Xia X, et al. Akt activation, but not extracellular signal-regulated kinase activation, is required for SDF-1a/CXCR4-mediated migration of epitheloid carcinoma cells. Mol Cancer Res 2005;3:227-36.
7. Zhou Y, Larsen PH, Hao C, Yong VW.CXCR4 is a major chemokine receptor on glioma cells and mediates their survival. J Biol Chem 2002;277:49481-7.
8. Rubin JB, Kung AL, Klein RS, Chan JA, Sun Y, Schmidt K, et al. A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci U S A 2003;100:13513-8.
9. Bertolini F, Dell'Agnola C, Mancoso P, Robascia C, Burlini A, Monestirolis S, et al. CXCR4 neutralization, a novel therapeutic approach for non-Hodgkin's lymphoma. Cancer Res 2002;62:3106-12.
10. Darash-Yahana M, Pikarsky E, Abramovitch R, Zeira E, Pal B, Karplus R, et al. A role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis. FASEB J 2004;18:1240-2.
11. Kioi M, Vogel H, Schultz G, Hoffman RM, Harsh GR, Brown JM. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest 2010;120:694-705
12. MoW, Chen J, Patel A, Zhang L, Chau V, Li Y, et al. CXCR4/CXCL12 mediate autocrine cell-cycle progression in NF-1-associated malignant peripheral nerve sheath tumors. Cell 2013;152:1077-90.
13. Yu L, Cecil J, Peng SB, Schrementi J, Kovacevic S, Paul D, et al. Identification and expression of novel isoforms of human stromal cell-derived factor 1. Gene 2006;374:174-9.
14. Debnath B, Xu S, Grande F, Garofalo A, Neamati N. Small molecule inhibitors of CXCR4. Theranostics 2013;3:47-75.
15. Labrosse B, Brelot A, Heveker N, Sol N, Schols D, De Clercq E, et al. Determinants for sensitivity of human immunodeficiency virus coreceptor CXCR4 to the bicyclam AMD3100. J Virol 1998;72:6381-8.
16. Hendrix CW, Collier AC, Lederman MM, Schols D, Pollard RB, Brown S, et al. Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic Syndr 2004;37:1253-62.
17. Oishi S, Fujii N. Peptides and peptidomimetic ligands for CXC chemokine receptor 4 (CXCR4). Org Biomol Chem 2012;10:5720-31.
18. Peled A, Abraham M, Avivi I, Rowe JM, Beider K, Wald H, et al. The high af finity CXCR4 antagonist BKT140 is safe and induces a robust mobilization of human CD34+ cells in patientwith multiplemyeloma.Clin Cancer Res 2014;20:469-79.
19. Kwong J, Kulbe H, Wong D, Chakravarty P, Balkwill F. An antagonist of chemokine receptor CXCR4 induces mitotic catastrophe in ovarian cancer cell. Mol Cancer Ther 2009;8:1893-905.
20. Galsky MD, Vogelzang NJ, Conkling P, Abu-Raddad E, Polzer J, Roberson S, et al. A phase I trial of LY2510924, a CXCR4 peptide antagonist, in patients with advanced cancer. Clin Cancer Res 2014;20:3581-8.
21. DeLapp NW, McKinzei JH, Sawyer BD, Vandergriff A, Falcone J, McClure D, et al. Determination of [35S] guanosine-5′-O-(3-thio) triphosphate binding mediated by cholinergic muscarinic receptors in membranes from Chinese hamster ovary cells and rat striatum using an anti-G-protein scintillation proximity assay. J Pharmacol Exp Ther 1999;289:946-55.
22. Falcon BL, Steward J, Ezell S, Hanson J, Wijsman J, Ye X, et al.High-content multiplexed tissue imaging and quantification for cancer drug discovery. Drug Dis Today 2013;18:510-22.
23. WuB, Chien EY, Mol CD, Fenalti G, Liu W, Katritch V, et al. Structures of the CXCR4 chemokine GPCR with small molecule and cyclic peptide antagonists. Sciences 2010;330:1066-71.
24. Gil M, Sehadri M, Komorowski MP, Abrams SI, Kozbor D. Targeting CXCL12/CXCR4 signaling with oncolytic virotherapy disrupt tumor vasculature and inhibits breast cancer metastasis. Proc Natl Acad Sci U S A 2013;110:e1291-300.
25. Ling X, Spaeth E, Chen Y, Shi Y, Zhang W, Schober W, et al. The CXCR4 antagonist AMD3465 regulated oncogenic signaling and invasiveness in vitro and prevents breast cancer growth and metastasis in vivo. PLoS ONE 2013;8:e58426.
26. Micallef IN, Stiff PJ, DiPersio JF, Maziarz RT, McCarty JM, Bridger G, et al. Successful stem cell remobilization using plerixafor (Mozobil) plus granulocyte colony-stimulating factor in patients with non-Hodgkin lymphoma: results from the plerixafor NHL phase 3 study rescue protocol. Biol Blood Marrow Tansplant 2009;15:1578-86.
27. DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL, et al. Plerixafor and G-CSF verse placebo and G-CSF to mobilize hematopoietic stem cells for autologues stem cell transplantation in patient with multiple myeloma. Blood 2009;113:5720-6.
28. Stone ND, Dunaway SB, Flexner C, Tierney C, Calandra GB, Becker S, et al. Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, as a selective CXCR4 receptor inhibitor, in human subjects. Antiomicrob Agents Chemother 2007;51:2351-8.
29. Ganju RK, Brubaker SA, Meyer J, Dutt P, Yang Y, Qin S, et al. The alpha-chemokine, stromal cell-derived factor-1 alpha, binds to the transmembrane G-protein-coupled CXCR-4 receptor and activates multiple signal transduction pathways. J Biol Chem 1998;273:23169-75.
30. Yu T, Wu Y, Huang Y, Yan C, Liu Y, Wang Z, et al. RNAi targeting CXCR4 inhibits tumor growth through inducing cell cycle arrest and apoptosis. Mol Ther 2012;20:398-407.
31. Kijima T, Maulik G, Ma PC, Tibaldi EV, Turner RE, Rollins B, et al. Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells. Cancer Res 2002;62:6304-11.
32. Vanharanta S, Shu W, Brenet F, Hakimi AA, Heguy A, Viale A, et al. Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer. Nat Med 2013;19:50-6.
33. Zeelenberg IS, Ruuls-Van Stalle L, Roos E. The chemokine receptor CXCR4 is required for outgrowth of colon carcinomamicrometastasis. Cancer Res 2003;63:3833-9.
34. Tavernier-Tardy E, Cornillon J, Campos L, Flandrin P, Duval A, Nadal N, et al. Prognostic value of CXCR4 and FAK expression in acute myelogenous leukemia. Leuk Res 2009;33:764-8.
35. Hartmann T, Burger J, Glodek A, Fujii N, Burger M. CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells. Oncogene 2005;24:4462-71.
36. UyGL, Rettig MP, Motabi IH, McFarland K, Trinkaus KM, Hladnik LM, et al. A phase 1/2 study of chemosensitizationwith the CXCR4 antagonist plerixafor in relapsed or refractory acutemyeloid leukemia. Blood 2012;119:3917-24.
37. Smith MC, Luker KE, Garbow JR, Prior JL, Jackson E, Piwnica-Worms D, et al. CXCR4 regulates growth of both primary andmetastatic breast cancer. Cancer Res 2004;64:8604-12.
38. Righi E, Kashiwagi S, Yuan J, Santosuosso M, Leblanc P, Ingraham R, et al. CXCl12/CXCR4 blockade induces multimodel antitumor effects that prolong survival in a immunocompetent mouse model of ovarian cancer. Cancer Res 2011;71:5522-34.
39. Feig C, Jones JO, Kraman M, Wells RJ, Deonarine A, Chan DS. Et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A 2013;110:20212-7.